|

3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)

RECRUITINGN/ASponsored by University Hospital, Bordeaux
Actively Recruiting
PhaseN/A
SponsorUniversity Hospital, Bordeaux
Started2023-08-02
Est. completion2026-05-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05227092

Summary

The aim of this study is to compare the 3D OPTIMIZED MPRAGE WMN sequence to "conventional sequences" used in spinal cord analysis. The patients will be explored at the cervical level with the conventional 2D sagittal T2 FSE, 2D sagittal STIR, 2D sagittal PSIR, 3D T1 MPRAGE sequences, and the sequence of interest 3D sagittal OPTIMIZED WMN MPRAGE and 3D axial OPTIMIZED WMN MPRAGE. At the thoracic level, with the conventional 2D sagittal T2 FSE, 2D sagittal STIR, 3D T1 MPRAGE sequences and the sequence of interest 3D sagittal OPTIMIZED WMN MPRAGE.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients older than 18 years old
* CIS or RRMS
* Medullary symptomatology less than 6 months
* With or without an objective lesion on a subsequent MRI scan
* Signed the Informed Consent

Exclusion Criteria:

* Pregnant or potentially pregnant women
* Breastfeeding woman
* Contraindications to MRI
* Other diagnosis (Neuro-myelitis spectrum disease or Progressive Multiple Sclerosis)
* Surgical history on the spinal cord or lumbar spine
* Patient under legal protection

Conditions1

Multiple Sclerosis

Browse More Trials

Multiple Sclerosis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.